AWH Quote, Financials, Valuation and Earnings

Azenta has a net margin of -157.16% compared to Aspira Womens Health's net margin of -9.04%. Aspira Womens Health's return on equity of -1961.68% beat Azenta's return on equity of -7.97%.

Aspira Womens Health has a consensus price target of --, signalling upside risk potential of 4561.02%. On the other hand Azenta has an analysts' consensus of $58.67 which suggests that it could grow by 58.78%. Given that Aspira Womens Health has higher upside potential than Azenta, analysts believe Aspira Womens Health is more attractive than Azenta.

Aspira Womens Health has a beta of 1.569, which suggesting that the stock is 56.912% more volatile than S&P 500. In comparison Azenta has a beta of 1.521, suggesting its more volatile than the S&P 500 by 52.14%.

Aspira Womens Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aspira Womens Health pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

Aspira Womens Health quarterly revenues are $2.3M, which are smaller than Azenta quarterly revenues of $147.5M. Aspira Womens Health's net income of -$3.5M is higher than Azenta's net income of -$13.3M. Notably, Aspira Womens Health's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aspira Womens Health is 0.17x versus 2.86x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bionano Genomics has a net margin of -157.16% compared to Aspira Womens Health's net margin of -728.57%. Aspira Womens Health's return on equity of -1961.68% beat Bionano Genomics's return on equity of -158.95%.

Aspira Womens Health has a consensus price target of --, signalling upside risk potential of 4561.02%. On the other hand Bionano Genomics has an analysts' consensus of -- which suggests that it could grow by 1718.18%. Given that Aspira Womens Health has higher upside potential than Bionano Genomics, analysts believe Aspira Womens Health is more attractive than Bionano Genomics.

Aspira Womens Health has a beta of 1.569, which suggesting that the stock is 56.912% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.247, suggesting its more volatile than the S&P 500 by 124.652%.

Aspira Womens Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aspira Womens Health pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

Aspira Womens Health quarterly revenues are $2.3M, which are smaller than Bionano Genomics quarterly revenues of $6.1M. Aspira Womens Health's net income of -$3.5M is higher than Bionano Genomics's net income of -$44.2M. Notably, Aspira Womens Health's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aspira Womens Health is 0.17x versus 0.08x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -157.16% compared to Aspira Womens Health's net margin of 1.4%. Aspira Womens Health's return on equity of -1961.68% beat Bruker's return on equity of 6.78%.

Aspira Womens Health has a consensus price target of --, signalling upside risk potential of 4561.02%. On the other hand Bruker has an analysts' consensus of $68.42 which suggests that it could grow by 46.56%. Given that Aspira Womens Health has higher upside potential than Bruker, analysts believe Aspira Womens Health is more attractive than Bruker.

Aspira Womens Health has a beta of 1.569, which suggesting that the stock is 56.912% more volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.406%.

Aspira Womens Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.43% to investors and pays a quarterly dividend of $0.05 per share. Aspira Womens Health pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Aspira Womens Health quarterly revenues are $2.3M, which are smaller than Bruker quarterly revenues of $979.6M. Aspira Womens Health's net income of -$3.5M is lower than Bruker's net income of $13.7M. Notably, Aspira Womens Health's price-to-earnings ratio is -- while Bruker's PE ratio is 61.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aspira Womens Health is 0.17x versus 2.07x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of -157.16% compared to Aspira Womens Health's net margin of 0.07%. Aspira Womens Health's return on equity of -1961.68% beat Harvard Bioscience's return on equity of -18.36%.

Aspira Womens Health has a consensus price target of --, signalling upside risk potential of 4561.02%. On the other hand Harvard Bioscience has an analysts' consensus of $4.25 which suggests that it could grow by 517.19%. Given that Aspira Womens Health has higher upside potential than Harvard Bioscience, analysts believe Aspira Womens Health is more attractive than Harvard Bioscience.

Aspira Womens Health has a beta of 1.569, which suggesting that the stock is 56.912% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.371%.

Aspira Womens Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aspira Womens Health pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Aspira Womens Health quarterly revenues are $2.3M, which are smaller than Harvard Bioscience quarterly revenues of $24.6M. Aspira Womens Health's net income of -$3.5M is lower than Harvard Bioscience's net income of $18K. Notably, Aspira Womens Health's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aspira Womens Health is 0.17x versus 0.32x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.